ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review.
Nikhita Kathuria-PrakashLidia P LopezSteven RamanHuihui YeJordan AnaokarAnthony SiskAllan J PantuckAlexandra DrakakiPublished in: JCO precision oncology (2024)
ALK-rearranged RCC refractory to several lines of treatment has a durable response when treated with alectinib.